Trials / Withdrawn
WithdrawnNCT02627820
The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart
An 18 Month Open Label Study Of The Tolerability And Efficacy Of An Antisense Oligonucleotide In Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy (Senile Systemic Amyloidosis)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
ATTRwt (also known as senile systemic, or senile cardiac amyloidosis) is a progressive heart disease, causing congestive heart failure. It is caused by amyloid protein deposits in the heart, that are derived from a normal protein, TTR, made in the liver. The aim of the study is to determine whether lowering the blood levels of TTR, by a weekly injection of a compound designed specifically to do this, will slow the progression of the disease when treated patients are compared to previously-followed patients who were not receiving this drug. The study also aims to determine how well this drug is tolerated and the existence and severity of any drug side-effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Isis 420915/GSK 299872 | Open label study in comparison to historic control. |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2015-12-11
- Last updated
- 2016-08-10
Source: ClinicalTrials.gov record NCT02627820. Inclusion in this directory is not an endorsement.